We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) infection, to evaluate the long-term efficacy of antisense oligonudeotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of IiV-1 RNA, blocked replication of the virus in a sequencespecific manner at 1 pM concentration. Variations in antiviral activity were seen among the different oligonucleotides, revealing an effect of target selection. Mismatched or random oligonucleotide phosphorothioates delayed, but did not completely inhibit, HIV-1 replication. In the case of inhibition by a splice-acceptor-site antisense oligodeoxynucleotide, a breakthrough phenomenon occurred after 25 days of treatment, suggesting the development ofan "escape mutant." This result did not occur when the inhibitory oligodeoxynucleotides were complementary to the primary-sequence areas of the revresponsive element and rev-i genes. Sequential treatment of HIV-1-infected cells with a combination of different antisense oligonucleotides, each administered once, also prevented the development of escape mutants. Our results suggest that chemotherapy based on specifically targeted antisense-oligonucleotide phosphorothioates may be an effective method for reducing the viral burden in HIV-1-infected individuals at clinically achievable oligonucleotide concentrations.
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One rationale for antiviral chemotherapy is based on the use of antisense oligonucleotides to inhibit specifically the expression of human immunodeficiency virus type 1 (HIV-1) (1) or other viruses (2) . Unmodified phosphodiester oligodeoxynucleotides, complementary to HIV-1 RNA, have been demonstrated to inhibit viral replication in early infected cells (3, 4) but not to inhibit viral replication in chronically infected cells (5) , mainly because of the nuclease susceptibility of these oligodeoxynucleotides (6) . Therefore, chemically modified nuclease-resistant analogs have been developed and studied for their effectiveness in inhibiting HIV-1 replication in tissue cultures (7) (8) (9) . Phosphorothioate-modified oligomers inhibit HIV-1 replication in both acute infection (5) (when virus is added to an uninfected susceptible-cell line) and in chronically infected cell lines (8, [10] [11] [12] , but even mismatched oligomers have some inhibitory activities in acutely infected cells. At low concentrations, these control oligomers are, however, less effective than the complementary oligomers.
MATERIALS AND METHODS
Synthesis of the Oligodeoxynucleotide Phosphorothioates. Phosphorothioate-modified oligodeoxynucleotides were synthesized by using H-phosphonate chemistry on an automated synthesizer (Millipore model 8700) on a 5-to 10-mmol scale. After assembly of the required sequence, the controlled-pore glass-bound oligonucleotide H-phosphonate was oxidized with sulfur in pyridine/triethylamine/carbon disulfide to generate phosphorothioate linkages. The deprotection was completed in concentrated ammonia at 40TC for 48 hr. The oligonucleotides were purified by preparative reverse-phase chromatography and then ion-exchange chromatography. Finally, purified oligonucleotides were dialyzed against water and lyophilized. Oligonucleotide phosphorothioates were checked for their purity by HPLC and PAGE (5) .
Antisense and Control Oligonucleotides. To study the inhibition of HIV-1 replication, oligodeoxynucleotide phosphorothioates 28 bases long were chosen because specificity has been shown to be increased by length of the oligomers used at equivalent concentrations (11) . Five different target sequences ( Fig. 1 ) in the HIV-1 genome were selected. Because tat and rev can trans-activate HIV-1 gene expression and are essential for virus replication, two oligomers, rev-1 (10) and rev-2, complementary to these overlapping reading frames were evaluated. Rev regulates HIV gene expression through interaction with the Rev-responsive element (RRE). Therefore the RRE oligomer was directed against the RRE overlapping the known Rev-binding site (14, 15) . The RRE oligomer was chosen after screening a number of potential anti-RRE oligonucleotides. In addition to blocking the Rev-RRE interaction, RRE could potentially interfere with translation of the viral envelope gene. Another oligomer, designated gag, was directed against the mRNA of that structural gene. Oligonucleotide SA is complementary to the major splice-acceptor site of the first coding exon of the tat gene (16) , which is also located in the open reading frame of the nonessential vpr gene. To determine specificity of the antisense oligomers, the biological effect should be compared to the same-size oligomer that is not complementary to any known cellular or viral genes. We have chosen three control "nonspecific" types of oligonucleotides, of which the "Random" sequence is theoretically the best. The Random sequence was synthesized as a degenerate oligonucleotide, by coupling a mixture of 4 nucleotides at each stage (theoretically it contains 428 = 7.2 x 1016 sequences) and thus measures the extent of sequence-nonspecific inhibition. "Mismatch" has the SA sequence with 5 bases altered (Fig.  1, underlined (18) . The effect of antisense oligonucleotides on HIV-1 replication was tested in a CD4+ T-cell line (MOLT-3) infected with low multiplicity of infection of HIV-1 type IIIB. After 2 hr of infection, the cells were washed and treated with oligonucleotides. The initial infection is characterized by 3% positivity for p24 membrane expression after 4 days in untreated cells. Therefore, most cells remain CD4+ and, thus, susceptible to reinfection during the treatment period. Extending the treatment period over weeks rather than days simulates a treatment schedule that could be given to an HIV-1-infected individual.
The amount of drug used for long-term studies was determined, based on the minimal concentration that inhibited viral infection >60%6 in a 4-day study. Short-term inhibition by different oligomers (Fig. 2A) 
